1. Home
  2. PHVS vs CECO Comparison

PHVS vs CECO Comparison

Compare PHVS & CECO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHVS
  • CECO
  • Stock Information
  • Founded
  • PHVS 2015
  • CECO 1966
  • Country
  • PHVS Netherlands
  • CECO United States
  • Employees
  • PHVS N/A
  • CECO N/A
  • Industry
  • PHVS Biotechnology: Pharmaceutical Preparations
  • CECO Pollution Control Equipment
  • Sector
  • PHVS Health Care
  • CECO Industrials
  • Exchange
  • PHVS Nasdaq
  • CECO Nasdaq
  • Market Cap
  • PHVS 1.0B
  • CECO 913.0M
  • IPO Year
  • PHVS 2021
  • CECO N/A
  • Fundamental
  • Price
  • PHVS $18.17
  • CECO $31.47
  • Analyst Decision
  • PHVS Strong Buy
  • CECO Strong Buy
  • Analyst Count
  • PHVS 5
  • CECO 5
  • Target Price
  • PHVS $40.60
  • CECO $35.00
  • AVG Volume (30 Days)
  • PHVS 73.1K
  • CECO 249.8K
  • Earning Date
  • PHVS 11-13-2024
  • CECO 10-29-2024
  • Dividend Yield
  • PHVS N/A
  • CECO N/A
  • EPS Growth
  • PHVS N/A
  • CECO N/A
  • EPS
  • PHVS N/A
  • CECO 0.33
  • Revenue
  • PHVS N/A
  • CECO $553,078,000.00
  • Revenue This Year
  • PHVS N/A
  • CECO $8.05
  • Revenue Next Year
  • PHVS N/A
  • CECO $19.79
  • P/E Ratio
  • PHVS N/A
  • CECO $91.80
  • Revenue Growth
  • PHVS N/A
  • CECO 8.97
  • 52 Week Low
  • PHVS $15.37
  • CECO $18.50
  • 52 Week High
  • PHVS $33.00
  • CECO $35.16
  • Technical
  • Relative Strength Index (RSI)
  • PHVS 51.83
  • CECO 51.55
  • Support Level
  • PHVS $18.18
  • CECO $28.70
  • Resistance Level
  • PHVS $19.88
  • CECO $31.18
  • Average True Range (ATR)
  • PHVS 1.11
  • CECO 1.16
  • MACD
  • PHVS 0.17
  • CECO -0.24
  • Stochastic Oscillator
  • PHVS 76.86
  • CECO 34.61

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

About CECO CECO Environmental Corp.

CECO Environmental Corp serves the energy, industrial, and other niche markets. The company operates through the Engineered Systems segment that serves the power generation, refinery, water/wastewater, and midstream oil and gas markets, and Industrial Process Solutions segment, which serves the broad industrial air pollution control, beverage can, fluid handling, electric vehicle production, food and beverage, semi-conductor, process filtration, pharmaceutical, petrochemical, wastewater treatment, wood manufacturing, desalination, and aquaculture markets. The majority of revenue is earned from the Engineered Systems Segment.

Share on Social Networks: